VolitionRx Limited Amortization of Debt Discount (Premium)
VolitionRx Limited (VNRX) reported Amortization of Debt Discount (Premium) of $405.07 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-08-13
- VolitionRx Limited amortization of debt discount (premium) for the quarter ending 2026-06-30 was $405.07K, a 24.52% increase year-over-year.
- VolitionRx Limited amortization of debt discount (premium) for the quarter ending 2026-03-31 was $450.13K.
- VolitionRx Limited amortization of debt discount (premium) for the quarter ending 2025-12-31 was $902.21K.
- VolitionRx Limited amortization of debt discount (premium) for the quarter ending 2025-09-30 was $729.63K.
- VolitionRx Limited amortization of debt discount (premium) for fiscal 2025 was $1.96M.
- VolitionRx Limited amortization of debt discount (premium) for fiscal 2024 was $0.00.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $405.07K 10-Q · filed 2026-08-13 | $855.20K 10-Q · filed 2026-08-13 | $1.76M derived: sum of 3 quarters · filed 2026-08-13 | $2.49M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $450.13K 10-Q · filed 2026-05-14 | $1.35M derived: sum of 2 quarters · filed 2026-05-14 | $2.08M derived: sum of 3 quarters · filed 2026-05-14 | $2.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $902.21K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.63M derived: sum of 2 quarters · filed 2026-03-31 | $1.96M derived: sum of 3 quarters · filed 2026-08-13 | $1.96M 10-K · filed 2026-03-31 |
| 2025-09-30 | $729.63K 10-Q · filed 2025-11-13 | $1.05M derived: sum of 2 quarters · filed 2026-08-13 | $1.05M 10-Q · filed 2025-11-13 | $1.05M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $325.31K 10-Q · filed 2026-08-13 | $325.31K 10-Q · filed 2026-08-13 | $325.31K derived: sum of 3 quarters · filed 2026-08-13 | $325.31K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $0.00 derived: sum of 3 quarters · filed 2026-05-14 | $0.00 derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | $0.00 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |